Danoprevir 2-yl)ethane-1 2-diamine hydrochloride InChi: InChI=1S/C27H31FN4O2/c1-19-9-6-7-14-24(19)26(27(34)30-22-11-4-3-5-12-22)32(23-13-8-10-21(28)17-23)25(33)18-31-16-15-29-20(31)2/h6-10

InChi: InChI=1S/C27H31FN4O2/c1-19-9-6-7-14-24(19)26(27(34)30-22-11-4-3-5-12-22)32(23-13-8-10-21(28)17-23)25(33)18-31-16-15-29-20(31)2/h6-10

PF-03716556 inhibits gastric acid secretion in rat and dog models

SKL2001 is an agonist of the Wnt/β-catenin pathway

Astilbin undergoes extensive biotransformation specifically due to enzyme catechol-O-methyl transferase

a protein that guards and repairs the neuronal genome

Danoprevir 2-yl)ethane-1 2-diamine hydrochloride InChi: InChI=1S/C27H31FN4O2/c1-19-9-6-7-14-24(19)26(27(34)30-22-11-4-3-5-12-22)32(23-13-8-10-21(28)17-23)25(33)18-31-16-15-29-20(31)2/h6-10Danoprevir, also known as ITMN 191 and RG 7227, is under development by InterMune Inc and Roche Holding AG, is a promising, potent NS3 4A protease inhibitor for the oral treatment of HCV infection. Preclinical data demonstrated that danoprevir binds with high affinity and dissociates slowly from the HCV NS3 protease, allowing high liver drug exposure with only modest plasma drug exposure. A phase Ib, 'IFN free' clinical trial demonstrated that